How to buy Catalyst Pharmaceuticals stock (CPRX)

Catalyst Pharmaceuticals is a biotechnology business based in the US. Catalyst Pharmaceuticals shares (CPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $21.27 – a decrease of 0.51% over the previous week. Catalyst Pharmaceuticals employs 167 staff and has a trailing 12-month revenue of around $460.5 million.

Our top picks for where to buy Catalyst Pharmaceuticals stock

Buy Catalyst Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Catalyst Pharmaceuticals stock price (NASDAQ: CPRX)

Use our graph to track the performance of CPRX stocks over time.

Catalyst Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$21.27
52-week range	$13.12 - $24.27
50-day moving average more info button	$21.65
200-day moving average more info button	$18.21
Wall St. target price	$32.25
PE ratio more info button	18.0932
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$1.18

Is it a good time to buy Catalyst Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Catalyst Pharmaceuticals price performance over time

Historical closes compared with the close of $21.27 from 2024-12-20

1 week (2024-12-13)	-0.51%
1 month (2024-11-22)	-0.98%
3 months (2024-09-20)	2.31%
6 months (2024-06-21)	36.43%

1 year (2023-12-22)	28.29%
2 years (2022-12-22)	9.92%
3 years (2021-12-22)	204.29%
5 years (2019-12-20)	459.74%

Is Catalyst Pharmaceuticals stock undervalued or overvalued?

Valuing Catalyst Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalyst Pharmaceuticals's P/E ratio

Catalyst Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Catalyst Pharmaceuticals shares trade at around 18x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Catalyst Pharmaceuticals's EBITDA

Catalyst Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $211.4 million.

The EBITDA is a measure of a Catalyst Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Catalyst Pharmaceuticals financials

Revenue TTM	$460.5 million
Operating margin TTM	39.56%
Gross profit TTM	$160 million
Return on assets TTM	18.35%
Return on equity TTM	28.29%
Profit margin	31.01%
Book value	$5.54
Market Capitalization more info button	$2.5 billion

TTM: trailing 12 months

Catalyst Pharmaceuticals share dividends

We're not expecting Catalyst Pharmaceuticals to pay a dividend over the next 12 months.

Catalyst Pharmaceuticals share price volatility

Over the last 12 months, Catalyst Pharmaceuticals's shares have ranged in value from as little as $13.1161 up to $24.27. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Pharmaceuticals's is 0.755. This would suggest that Catalyst Pharmaceuticals's shares are less volatile than average (for this exchange).

Catalyst Pharmaceuticals overview

Catalyst Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc. ; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Frequently asked questions

What percentage of Catalyst Pharmaceuticals is owned by insiders or institutions?
Currently 6.092% of Catalyst Pharmaceuticals shares are held by insiders and 82.586% by institutions. How many people work for Catalyst Pharmaceuticals?
Latest data suggests 167 work at Catalyst Pharmaceuticals. When does the fiscal year end for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals's fiscal year ends in December. Where is Catalyst Pharmaceuticals based?
Catalyst Pharmaceuticals's address is: 355 Alhambra Circle, Coral Gables, FL, United States, 33134 What is Catalyst Pharmaceuticals's ISIN number?
Catalyst Pharmaceuticals's international securities identification number is: US14888U1016 What is Catalyst Pharmaceuticals's CUSIP number?
Catalyst Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 14888U101